Spyglass Pharma, Inc. is a clinical-stage biopharmaceutical company dedicated to revolutionizing the treatment of chronic ophthalmic diseases through its innovative drug delivery platform. The company's primary focus is on addressing the challenges of patient compliance and the limitations of traditional eye drop therapies, which are often the standard of care for conditions like glaucoma. Spyglass Pharma's core technology is a proprietary drug-eluting intraocular lens (IOL) platform. This system is designed to be implanted during routine cataract surgery, providing a controlled, long-term release of medication directly into the eye. By automating drug delivery at the source, the company aims to provide a more consistent and effective treatment regimen for patients suffering from glaucoma and ocular hypertension, significantly reducing the burden of daily self-administration. The company's lead product candidate utilizes this platform to deliver bimatoprost, a well-established medication for lowering intraocular pressure, over an extended period. This approach seeks to eliminate the high rates of non-compliance associated with topical drops. Spyglass Pharma is currently advancing its platform through clinical trials to establish the safety and efficacy of its delivery system. Headquartered in Aliso Viejo, California, Spyglass Pharma was co-founded by industry veterans and clinicians with extensive experience in ophthalmology and medical device development. The company is supported by leading venture capital investors and continues to explore the application of its technology to a broader range of ocular conditions beyond its initial focus on glaucoma.
How many years of EBITDA are required to pay off the company's net debt, according to the official accounting standard IFRS16. As a market consensus, a value of up to 3 years of leverage is accepted for most companies.
How much the company's debt represents in % in relation to its equity. As a market consensus, a value less than or equal to 1 is accepted, above that leverage can end up hurting the final result at some point.
The current ratio helps investors understand more about a company's ability to cover its short-term debt with its current assets and make apples-to-apples comparisons with its competitors and peers.
The quick ratio measures a company's capacity to pay its current liabilities without needing to sell its inventory or obtain additional financing and is considered a more conservative measure than the current ratio, which includes all current assets as coverage for current liabilities.
The interest coverage ratio is used to measure how well a firm can pay the interest due on outstanding debt and is is calculated by dividing a company's earnings before interest and taxes (EBIT) by its interest expense during a given period. Generally, a higher coverage ratio is better, although the ideal ratio may vary by industry.
...and much more!